Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;11(2):221-30.
doi: 10.1517/17425255.2015.983073. Epub 2014 Nov 21.

Animal models for exploring the pharmacokinetics of breast cancer therapies

Omar M Rashid  1 , Kazuaki Takabe
Affiliations
Review

Animal models for exploring the pharmacokinetics of breast cancer therapies

Omar M Rashid et al. Expert Opin Drug Metab Toxicol. 2015 Feb.

Abstract

Introduction: Despite massive expenditures in research and development to cure breast cancer, few agents that pass preclinical trials demonstrate efficacy in humans. Although this endeavor relies on murine models to screen for efficacy before progressing to clinical trials, historically there has been little focus on the validation of these models, even in the era of targeted therapy where understanding the genetic signatures of tumors under study is critical.

Areas covered: This review includes the transgenic, xenograft, and syngeneic murine breast cancer models, the ectopic, orthotopic and intravenous methods of cell implantation, and the ethics of animal experimentation. It also includes the latest data on tumor gene expression and the issues to consider when exploring the pharmacokinetics and efficacy of breast cancer therapies.

Expert opinion: Breast cancer drug development is expensive and inefficient without a consensus preclinical murine model. Investigators must approach the choice of murine model with the same sophistication that is applied to the choice of in vitro assays to improve efficiency. Understanding the limitations of each model available, including the nuances of tumor gene signatures, is critical for investigators exploring the phamacokinetics and efficacy of breast cancer therapies, especially in the context of gene profiling and individualized targeted therapy.

Keywords: breast cancer drug development; murine metastatic model.

PubMed Disclaimer

References

    1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014;64(1):9–29. - PubMed
    1. Light DW. Global drug discovery: Europe is ahead. Health Aff (Millwood) 2009;28(5):w969–977. - PubMed
    1. Adams CP, Brantner VV. Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff (Millwood) 2006;25(2):420–428. * Elegant description of the inefficiencies of drug development. - PubMed
    1. Schuh JC. Trials, tribulations, and trends in tumor modeling in mice. Toxicol Pathol. 2004;32(Suppl 1):53–66. * Classic review of animal models for cancer research. - PubMed
    1. Burger MM. Uicc study group on basic and clinical cancer research: Animal models for the natural history of cancer. Meeting held at woods hole, ma (USA), june 21-23, 1999. International union against cancer. International journal of cancer Journal international du cancer. 2000;85(3):303–305. - PubMed

Publication types

Substances